Injectoplast Profile
Key Indicators
- Authorised Capital ₹ 3.25 Cr
as on 06-12-2024
- Paid Up Capital ₹ 3.20 Cr
as on 06-12-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 30.46 Cr
as on 06-12-2024
- Revenue %
(FY 2022)
- Profit 90.66%
(FY 2022)
- Ebitda 97.39%
(FY 2022)
- Net Worth -12.30%
(FY 2022)
- Total Assets -38.57%
(FY 2022)
About Injectoplast
The Company is engaged in the Automotive Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.25 Cr and a paid-up capital of Rs 3.20 Cr.
The company currently has active open charges totaling ₹30.46 Cr.
Ram Shah, Arun Shah, Abhishek Shah, and Three other members serve as directors at the Company.
- CIN/LLPIN
U25209UP2020PTC134607
- Company No.
134607
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Sep 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Injectoplast?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Shah  | Managing Director | 14-Sep-2020 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ayush Pandey | Director | 27-Mar-2023 | Current |
| Abhishek Shah | Director | 28-Jun-2023 | Current |
| Ram Shah | Director | 17-Jan-2023 | Current |
| Akshay Bajaj | Additional Director | 01-Aug-2024 | Current |
| Devansh Bajaj | Additional Director | 01-Aug-2024 | Current |
Financial Performance of Injectoplast.
Injectoplast Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 90.66% increase in profit. The company's net worth observed a substantial decline by a decrease of 12.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Injectoplast?
In 2022, Injectoplast had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Abhishek Finsec Private LimitedActive 28 years 5 months
Arun Shah and Abhishek Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Oct 2024 | ₹4.58 M | Open |
Others Creation Date: 07 Jul 2024 | ₹15.00 Cr | Open |
Axis Bank Limited Creation Date: 02 Jan 2024 | ₹15.00 Cr | Open |
How Many Employees Work at Injectoplast?
Injectoplast has a workforce of 0 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Injectoplast, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Injectoplast's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
